Related by context. All words. (Click for frequent words.) 78 tumor recurrence 78 distant metastasis 76 lymph node involvement 76 metastases 74 metastatic disease 73 lymph node metastases 73 lymph node metastasis 72 biochemical recurrence 72 locoregional recurrence 72 locoregional 71 advanced adenomas 71 breast carcinoma 71 neoadjuvant therapy 71 nodal metastases 71 micrometastases 70 neoadjuvant chemotherapy 70 pancreatic adenocarcinoma 70 EBRT 69 node metastases 69 liver metastases 69 liver metastasis 69 cystectomy 69 advanced adenoma 69 pT3 69 adenoma 68 axillary lymph nodes 68 preoperative chemotherapy 68 metastatic lesions 68 ALND 68 axillary dissection 68 adjuvant radiotherapy 68 contralateral breast 68 nodal metastasis 68 curative resection 68 chemoradiotherapy 67 lobular carcinoma 67 PCa 67 lymphadenectomy 67 tumor resection 67 axillary nodes 67 metastatic prostate cancer 67 contralateral breast cancer 67 operable breast cancer 67 radiochemotherapy 67 postoperative chemotherapy 67 adjuvant therapy 67 pCR 67 invasive carcinoma 67 renal tumors 67 SLNB 67 atypical hyperplasia 66 adjuvant radiation 66 adenomatous polyps 66 axillary node 66 clinically localized prostate 66 PSA nadir 66 metachronous 66 cytoreductive surgery 66 chemoradiation 66 HNSCC 66 renal cell carcinomas 66 prostate cancer CaP 66 biochemical relapse 66 lymph node dissection 66 lymphocytosis 66 malignancy 66 EUS FNA 66 underwent resection 66 PSADT 66 colorectal adenoma 66 HER2 negative 66 metastatic RCC 66 prostate carcinoma 66 metastatic cancer 66 ovarian carcinoma 66 CMV disease 66 pulmonary metastases 66 metastatic tumors 66 urothelial carcinoma 66 lymph nodes 65 micrometastasis 65 metastatic lung cancer 65 axillary lymph node 65 esophageal carcinoma 65 CIN3 65 adrenalectomy 65 lung metastases 65 gastric adenocarcinoma 65 pelvic lymphadenectomy 65 resected 65 radical nephrectomy 65 extracapsular extension 65 androgen deprivation 65 cervical carcinoma 65 adjuvant chemotherapy 65 lymph node 65 epithelial tumors 65 neoadjuvant 65 endometrial carcinoma 65 reintervention 65 colorectal carcinoma 65 sentinel lymph node biopsy 65 Radical prostatectomy 65 intestinal metaplasia 65 GISTs 65 cytoreduction 65 atypia 65 IV NSCLC 64 precursor lesions 64 endometrial cancers 64 histologically confirmed 64 pT2 64 postoperative morbidity 64 seminal vesicle invasion 64 adenocarcinomas 64 peritoneal carcinomatosis 64 resectable 64 hepatic metastases 64 nonmetastatic 64 malignant lesions 64 histologic subtype 64 MetS 64 stage IIIB 64 perioperative complications 64 adjuvant therapies 64 carcinoid tumors 64 neoplasm 64 lymphadenopathy 64 postoperative radiotherapy 64 CaP 64 lymphovascular invasion 64 ductal breast cancer 64 histologic 64 #.#ng/ml 64 HSCT 64 axillary node dissection 64 sentinel nodes 64 liver transplant recipients 64 thromboembolic events 64 invasive ductal 64 estrogen receptor ER 64 histologically 64 carcinomas 64 histological subtype 64 metastatic 64 recurrent VTE 64 malignant neoplasm 63 renal carcinoma 63 radical prostatectomy RP 63 specific antigen PSA 63 postoperative complication 63 unresectable 63 HGPIN 63 radical cystectomy 63 sentinel node biopsy 63 axillary lymph node dissection 63 bladder cancers 63 radiotherapy RT 63 HBeAg negative 63 prostate adenocarcinoma 63 ipsilateral breast 63 HER2 positive cancers 63 univariate analysis 63 perioperative mortality 63 carcinoids 63 mucinous 63 HER2 positive tumors 63 para aortic 63 retroperitoneal 63 Lymph node 63 F FDG PET 63 liver resection 63 colorectal polyp 63 carcinoma 63 transitional cell carcinoma 63 fallopian tube carcinoma 63 prognostic variables 63 HER2 expression 63 clinically detectable 63 situ LCIS 63 gastric cancer 63 thyroid nodules 63 brain metastases 63 carcinoid tumor 63 Hurthle cell 63 infarct size 63 nasopharyngeal carcinoma 63 lobular carcinomas 63 sentinel node 63 advanced neoplasia 63 MACCE 63 recurrences 63 TACE 63 mediastinal 63 P = .# 63 KRAS mutations 63 EGFR mutation 63 BRCA mutations 63 metastasis 63 cervical lymph nodes 63 MGUS 63 epithelial ovarian cancer 63 HBeAg 63 node dissection 63 unresectable tumors 62 external beam radiotherapy 62 endosonography 62 hormone receptor negative 62 SUVmax 62 radioiodine therapy 62 revascularization procedures 62 ductal carcinomas 62 recurrent prostate cancer 62 metastatic gastric 62 Recurrence Score 62 hematologic toxicity 62 differentiated thyroid 62 soft tissue sarcomas 62 paragangliomas 62 macroalbuminuria 62 nephrectomy 62 intracranial hemorrhage ICH 62 oophorectomy 62 rebleeding 62 total thyroidectomy 62 zoledronic acid 62 postoperative mortality 62 bilateral oophorectomy 62 EGFR mutations 62 stage IIIb IV 62 malignant neoplasms 62 bone metastases 62 hepatocellular carcinoma 62 bladder tumors 62 heavily pretreated patients 62 nodal dissection 62 tumor histology 62 HBeAg seroconversion 62 colorectal adenomas 62 neoplasias 62 nonmelanoma skin cancers 62 catheter angiography 62 salpingo oophorectomy 62 T1a 62 neoplastic lesions 62 prognostic factors 62 neoplasia 62 thyroglobulin 62 colorectal liver metastases 62 CIN2 + 62 EpCAM expression 62 medullary thyroid cancer 62 definite stent thrombosis 62 epithelial ovarian 62 tumors 62 intraoperative complications 62 breast cancer recurrence 62 hemorrhagic complications 62 chronic GVHD 62 systolic dysfunction 62 CIN2 62 premalignant 62 cervical intraepithelial neoplasia 62 reoperation 62 endometrial hyperplasia 62 FDG PET 62 FOLFOX4 62 malignancies 62 severe neutropenia 62 NMIBC 62 papillary thyroid carcinoma 62 gadolinium enhanced 61 vertebral fracture 61 peritoneal cancer 61 tumoral 61 reinfarction 61 chlamydial infection 61 ADPKD 61 progesterone receptor negative 61 lobular breast cancer 61 completely resected 61 TRUS biopsy 61 bone metastasis 61 hypoperfusion 61 small lymphocytic lymphoma 61 neoplasms 61 sleeve lobectomy 61 retransplantation 61 varices 61 prostate cancer PCa 61 adenomatous 61 esophagogastric junction 61 neoplastic cells 61 complete cytogenetic 61 papillary thyroid cancer 61 breast carcinomas 61 papillary renal cell carcinoma 61 malignant lymphoma 61 stage IIIA 61 neoadjuvant treatment 61 occult metastases 61 recurrent NSCLC 61 K ras mutations 61 complete cytogenetic response 61 CCyR 61 preoperative PSA 61 imatinib therapy 61 serous ovarian cancer 61 prior chemotherapy regimens 61 endometrial 61 hepatocellular carcinoma HCC 61 estrogen receptor negative 61 neuroendocrine tumors 61 mesotheliomas 61 hepatectomy 61 lobular cancer 61 papillary 61 prospectively defined 61 androgen suppression 61 carcinoid 61 hamartomas 61 lymph node removal 61 lobectomy 61 grade dysplasia 61 intracerebral hemorrhage 61 proximal colon 61 prostate cancer CRPC 61 hepatic resection 61 pericardial effusion 61 metastatic malignant melanoma 61 sarcomatoid 61 % CI #.#-#.# [007] 61 serum PSA 61 adenocarcinoma 61 fibrinolysis 61 androgen ablation 61 lung metastasis 61 prognostic significance 61 CR nPR 61 radical prostatectomy 61 seminoma 61 grade cervical intraepithelial 61 prostate cancers 61 castration resistant prostate cancer 61 Kaplan Meier analysis 61 intravesical therapy 61 perioperative morbidity 61 cystic lesions 61 esophageal squamous cell carcinoma 61 pheochromocytoma 61 periprocedural 61 concurrent chemoradiation 61 cisplatin resistant 61 metastatic GIST 61 precancerous polyp 61 T1c 61 renal dysfunction 61 sentinel lymph nodes 61 mediastinal lymph nodes 61 histologically proven 61 octreotide LAR 61 HER2 positive metastatic breast 61 colorectal neoplasms 61 hypopituitarism 61 bronchogenic carcinoma 61 NNRTI resistance 61 recanalization 61 % CI #.#-#.# [003] 61 infarcts 61 colorectal adenocarcinoma 61 BRAF mutation 61 hormone receptor positive 61 R0 resection 61 urothelial cancer 61 cytogenetic response 61 nondiabetic patients 61 Circulating tumor cells 61 gastric cancers 61 astrocytoma 61 resections 61 ductal cancer 61 uveal melanoma 61 squamous 61 undetectable HBV DNA 61 skeletal metastases 61 femoral neck fracture 61 Tumor shrinkage 61 renal transplantation 61 Adjuvant chemotherapy 61 chemoradiation therapy 60 nephron sparing surgery 60 pneumonectomy 60 chemoembolization 60 Median survival 60 postoperative pulmonary 60 autologous transplants 60 amenorrhoea 60 colorectal tumors 60 squamous histology 60 poorer prognosis 60 ipsilateral stroke 60 basal cell carcinoma BCC 60 p# mutation 60 CMV infection 60 osteosarcomas 60 thymoma 60 polyp recurrence 60 KRAS wild 60 BRCA1 mutation carriers 60 hepatocellular carcinomas 60 thyroid carcinoma 60 gastrectomy 60 locoregional disease 60 thoracoscopic lobectomy 60 medically inoperable 60 axilla 60 MYCN amplification 60 squamous cell carcinoma SCC 60 grade gliomas 60 gastric carcinoma 60 FDG uptake 60 malignant pleural mesothelioma 60 colorectal cancer 60 distal colon cancer 60 graft occlusion 60 LV dysfunction 60 colorectal cancer CRC 60 recurrent metastatic 60 mammographic density 60 antiangiogenic therapy 60 benign lesions 60 adenomas 60 intestinal polyps 60 mg kg dose 60 estrogen receptor positive 60 renal insufficiency 60 follicular lymphoma 60 lung tumors 60 debulking surgery 60 myocardial ischemia 60 neoadjuvant chemoradiotherapy 60 benign polyps 60 prognostic indicator 60 BRCA2 mutation carriers 60 proteinuria 60 TP# mutations 60 basal cell nevus syndrome 60 symptomatic VTE 60 alkaline phosphatase ALP 60 esophageal cancers 60 heterotopic ossification 60 breast endometrial 60 rectal cancers 60 intraductal 60 pathologic fractures 60 supratentorial 60 plasma uric acid 60 Subgroup analyzes 60 hypercalcemia 60 multivariate analyzes 60 carotid stenosis 60 tumor shrinkage 60 cell carcinomas 60 invasive breast cancer 60 hepatorenal syndrome 60 mRCC 60 metastatic prostate 60 nonfatal MI 60 basal cell carcinomas 60 metastatic bladder 60 TNF antagonist 60 LVEF 60 tumor necrosis 60 ischemic lesions 60 cTnT 60 astrocytomas 60 troponin T 60 B7 H3 60 unresectable stage 60 KRAS mutation 60 seminomas 60 glycated hemoglobin levels 60 hyperplastic 60 cancer mCRC 60 invasive carcinomas 60 lymphopenia 60 virologic response 60 recurrent glioblastoma multiforme 60 metastatic lesion 60 lung adenocarcinomas 60 colorectal metastases 60 cutaneous melanoma 60 cutaneous squamous cell carcinoma 60 pre cancerous polyps 60 renal cell carcinoma 60 intratumoral 60 prognostic factor 60 metastatic renal cell carcinoma 60 thrombotic complications 60 recurrent ovarian 60 calculi 60 anaplastic 60 BRCA deficient 60 esophagectomy 60 mediastinoscopy 60 thrombotic events 60 Rectal cancer 60 HbF 60 variceal hemorrhage 59 non squamous NSCLC 59 gastric atrophy 59 recurrent ischemia 59 CC genotype 59 malignant growths 59 liver histology 59 leukemia AML 59 underwent surgical resection 59 alanine aminotransferase ALT 59 patients undergoing CABG 59 gastroesophageal junction 59 mRNA expression 59 breast lesions 59 TEAEs 59 cisplatin chemotherapy 59 renal parenchyma 59 thrombocytopenic 59 platelet reactivity 59 nonmetastatic prostate cancer 59 intravenous bisphosphonates 59 endoscopic resection 59 TNF blocker therapy 59 pelvic lymph nodes 59 urothelial 59 noncardiac 59 Recurrences 59 thrombi 59 leiomyomas 59 metastatic lymph nodes 59 recurrent venous thromboembolism 59 HER2 overexpression 59 microalbuminuria 59 IGFBP 59 virologic responses 59 nonischemic 59 axillary 59 left ventricular dysfunction 59 transurethral resection 59 pancreatic lung 59 perfusion defects 59 IV melanoma 59 hip BMD 59 patients evaluable 59 parathyroid 59 undetectable PSA 59 graft dysfunction 59 achieved ACR# 59 thromboembolism 59 Metastatic 59 histopathologic examination 59 surgical debulking 59 immunohistochemical staining 59 cT3 prostate cancer 59 elevated ALT 59 ALT flares 59 malignant transformation 59 paclitaxel eluting stents 59 colectomy 59 penetrance 59 ductal 59 Partial Responses 59 baseline LDH 59 oropharyngeal cancer 59 undergoing radical prostatectomy 59 BRCA mutation carriers 59 malignant polyps 59 GSTM1 59 serum concentrations 59 urinary bladder cancer 59 H. pylori eradication 59 Thal Dex 59 evaluable patients 59 adjuvant tamoxifen 59 clinicopathological features 59 GnRH agonist 59 mCRC patients 59 extranodal 59 repeat revascularization 59 mycophenolate mofetil 59 bowel cancers 59 leukopenia 59 febrile neutropenia 59 parenchymal 59 revascularization procedure 59 microvascular complications 59 elevated LDH 59 cervical lesions 59 gefitinib 59 FOLPI 59 urine cytology 59 TIMP 59 androgen suppression therapy 59 HCV infected 59 lung nodules 59 squamous cell cancers 59 cytogenetic responses 59 T1DM 59 serum thyroglobulin 59 HBeAg positive patients 59 albuminuria 59 anthracycline taxane 59 multivariable analysis 59 GIST tumors 59 CTNNB1 59 invasive ductal carcinoma 59 BRAF mutations 59 histologies 59 allogeneic stem cell 59 undergoing coronary artery 59 localized renal 59 mitomycin C 59 ovarian tumors 59 posttransplant 59 virologic failure 59 osteochondromas 59 nonalcoholic steatohepatitis NASH 59 underarm lymph nodes 59 neoplastic 59 atypical ductal hyperplasia 59 hormonal therapy 59 NSCLC 59 nonischemic cardiomyopathy 59 allogeneic SCT 59 resected pancreatic cancer 59 median PFS 59 premalignant lesions 59 5FU 59 ductal lobular 59 GSTP1 59 pathologic 59 univariate 59 perioperatively 59 nephropathy 59 hormone receptor status 59 ependymoma 59 neurologic complications 59 nephrotoxicity 59 HIV HCV coinfected 59 intrahepatic 59 Median progression 59 polypoid lesions 59 subclinical hypothyroidism 59 post thrombotic syndrome 59 cholangiocarcinoma 59 ipsilateral 59 scintigraphic 59 parenchyma 59 transplantation HCT 59 breast tumors 59 luminal 58 mutated K ras 58 biliary tract cancer 58 estramustine 58 Kaplan Meier curve 58 malperfusion 58 chorioamnionitis 58 5-fluorouracil/leucovorin 58 cytotoxic chemotherapy 58 endometrial thickness 58 grade glioma 58 ocular toxicity 58 progression TTP 58 AML MDS 58 Sentinel node biopsy 58 recurrent myocardial infarction 58 tumor lysis syndrome 58 CR CRu 58 metastatic neuroendocrine tumors 58 tamoxifen therapy 58 gefitinib Iressa 58 elevated transaminases 58 colorectal cancers 58 kidney cysts 58 parathyroid carcinoma 58 ASCUS 58 postintervention 58 diabetes mellitus DM 58 evaluable 58 percutaneous biopsy 58 atherosclerotic disease 58 obstructive coronary artery 58 pulmonary nodules 58 virological response 58 hematuria 58 pulmonary metastasis 58 cerebral vasospasm 58 chemoresistant 58 allogeneic bone marrow 58 MALT lymphoma 58 orthotopic 58 oncologic outcomes 58 reimplantation 58 serum testosterone 58 repigmentation 58 KRAS mutations occur 58 leiomyoma 58 proliferative diabetic retinopathy 58 aminotransferases 58 #Gy 58 rs# [002] 58 varicocele 58 pancreatic carcinoma 58 submandibular gland 58 activating mutations 58 cerebral infarction 58 serum calcium levels 58 GnRH agonists 58 clinicopathological 58 sonographically guided 58 cardiac dysfunction 58 subtrochanteric 58 kidney allograft 58 Prostate specific antigen 58 postoperative AF 58 FDG-PET/CT 58 ximelagatran 58 CsA 58 clodronate 58 pegylated liposomal doxorubicin 58 trastuzumab 58 cytoreductive nephrectomy 58 parous women 58 Subgroup analysis 58 ABCB1 58 coronary calcification 58 neointimal 58 LHRH receptor positive 58 serum creatinine levels 58 adnexal mass 58 renal cysts 58 serum ALT 58 follicular lymphomas 58 coronary revascularization 58 paroxysmal AF 58 schwannomas 58 BRAF V#E mutation 58 intact parathyroid hormone 58 papillary RCC 58 colorectal neoplasia 58 papillary carcinoma 58 Wilms tumors 58 CHD mortality 58 hydronephrosis 58 chromosomal mutations 58 appendiceal 58 flutamide 58 precancerous cervical 58 mitral regurgitation 58 serum phosphate 58 ventricular dysfunction 58 thyrotoxicosis 58 colorectal polyps 58 VT VF 58 uterine cancers 58 ACR# responses 58 PASI scores 58 heavily pretreated 58 hyperoxaluria 58 ejection fractions 58 relapsed MM 58 timepoint 58 orchiectomy 58 HBeAg negative patients 58 fine needle aspiration 58 complete remissions 58 castrate resistant 58 ischemic cardiomyopathy 58 NYHA class 58 bladder carcinoma 58 pituitary adenomas 58 mammary tumors 58 dose cohort 58 perfusion abnormalities 58 Hepatocellular Carcinoma HCC 58 nonsmall cell lung cancer 58 recurrent miscarriage 58 KRAS mutant tumors 58 binary restenosis 58 draining lymph nodes 58 spontaneous bacterial peritonitis 58 coronary stenosis 58 osteoid 58 fallopian tube cancers 58 pretransplant 58 TT genotype 58 posttreatment 58 periventricular 58 cisplatin 58 benign breast 58 nonalcoholic steatohepatitis 58 lesions 58 dacarbazine DTIC 58 acute aortic dissection 58 fibrinolytic therapy 58 alteplase 58 intima media thickness 58 revascularization 58 antibody titer 58 systemic toxicity 58 haematopoietic 58 ovarian cancers 58 hematopoietic cancers 58 liposarcoma 58 gastric cardia 58 autonomic dysfunction 58 μmol L 58 neoadjuvant radiation 58 p# mutations 58 comorbidities 58 SLN biopsy 58 choroidal neovascularization CNV 58 thymectomy 58 antitumor effect 58 disease progression 58 estimated glomerular filtration 58 CIMZIA ™ 58 BRCA1 mutations 58 NAbs 58 genotypic resistance 58 tumor subtypes 58 hepatic fibrosis 58 femoral neck fractures 58 extracapsular 58 upper gastrointestinal bleeding 58 histopathologic 58 thromboembolic 58 BCR ABL mutations 58 response pCR 58 preoperatively 58 Immunohistochemical analysis 58 infarct 58 autoantibodies 58 pre malignant lesions 58 breast cancers 58 resection 58 nodular 58 squamous cell 57 vaginal hysterectomy 57 homozygotes 57 nonproliferative 57 ascites 57 epirubicin 57 pancreatic cancers 57 curable cancers 57 rectal cancer 57 sentinel lymph node 57 advanced unresectable 57 malignant nodules 57 undergone radical prostatectomy 57 eGFR 57 adverse cytogenetics 57 renal pelvis 57 endocrine therapies 57 artery stenosis 57 remission CR 57 prostate biopsy 57 cranial irradiation 57 parathyroidectomy 57 hypercoagulable 57 idiopathic myelofibrosis 57 coronary artery stenosis 57 thromboembolic complications 57 taxane therapy 57 bypass grafting 57 gemcitabine chemotherapy 57 postoperative complications 57 CVD mortality 57 fibroadenomas 57 Metastatic breast cancer 57 5-FU/LV 57 ertapenem 57 varicoceles 57 incomplete revascularization 57 Immunohistochemical staining 57 SHPT 57 Carcinoma 57 advanced hepatocellular carcinoma 57 gallstone disease 57 partial nephrectomy 57 serum prostate 57 Doxil ® 57 supraclavicular 57 chemosensitivity 57 CTEPH 57 cervical lymph node 57 Flu Cy 57 endoleak 57 EXJADE 57 normal karyotype 57 TURP 57 intra abdominal abscess 57 endometrial cancer 57 urolithiasis 57 leiomyosarcoma 57 imatinib 57 preoperative radiotherapy 57 hypermethylation 57 lactate dehydrogenase 57 hypopharynx 57 symptomatic intracerebral hemorrhage 57 wedge resection 57 pulmonary toxicity 57 D dimer 57 WT1 57 CYPHER Stent 57 diffuse gastric 57 lobular 57 breast cancer subtypes 57 mediastinum 57 squamous cell carcinomas 57 tumor regressions 57 microsatellite instability 57 echogenicity 57 gastrointestinal cancers 57 nonvertebral fractures 57 metastatic pancreatic 57 standard chemotherapy regimens 57 cirrhotic patients 57 HBsAg 57 ovarian malignancy 57 extracranial 57 intraperitoneal chemotherapy 57 liver fibrosis 57 neointimal hyperplasia 57 immunocompetent 57 coinfected patients 57 leucopenia 57 prostatic adenocarcinoma 57 splenic 57 carotid plaques 57 sonographically 57 meningiomas 57 Fontan procedure 57 progesterone receptor PR 57 pancreatectomy 57 glioblastomas 57 prostatectomy 57 metastatic malignant 57 deep venous thromboses 57 mucosal healing 57 metastatic basal cell 57 Stent thrombosis 57 Papillary 57 overt nephropathy 57 thyroid carcinomas 57 bortezomib 57 HER2 positive 57 adenoma recurrence 57 T2DM 57 thromboembolic disease 57 mutated KRAS 57 situ DCIS 57 fibrosis 57 radiographic findings 57 atrophic gastritis 57 atheroma volume 57 multicentric 57 venous blood clots 57 laboratory abnormalities 57 renal allograft 57 AGILECT R 57 Colon polyps 57 PITX2 57 QTc prolongation 57 untreated metastatic melanoma 57 ERCC1 57 cellularity 57 HER2 receptor 57 oropharyngeal 57 lung carcinomas 57 SSc 57 preoperative 57 tumor metastases 57 PAOD 57 palliation 57 iNOS 57 pathologic diagnosis 57 hormone refractory 57 transfusion syndrome 57 myocardial infarctions 57 aneurysm rupture 57 VUR 57 APOL1 57 hsCRP levels 57 timepoints 57 Lp PLA 2 57 standard chemotherapy regimen 57 immunohistochemical 57 choriocarcinoma 57 multivariate Cox